nach oben

Current HIV/AIDS Reports

Erschienen in:

01.06.2013 | The Global Epidemic (Q Abdool Karim, Section Editor)

Antiretroviral Therapy for Prevention Is a Combination Strategy

verfasst von: Margaret L. McNairy, Myron Cohen, Wafaa M. El-Sadr

Erschienen in: Current HIV/AIDS Reports | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

In the past several years, the debate of “treatment vs prevention” has shifted with the introduction of the concept of “treatment as prevention,” (TasP), stemming from a series of compelling observational, ecological, and modeling studies as well as HPTN 052, a randomized clinical trial, demonstrating that use of ART is associated with a decrease in HIV transmission. In addition to TasP being viewed as 1 intervention in a combination strategy for HIV Prevention, TasP is, in and of itself, a combination of multiple interventions that need to be implemented with high coverage in order to achieve its potential impact.

Cohen MS, Holmes C, Padian N, Wolf M, Hirnschall G, Lo YR, et al. HIV treatment as prevention: how scientific discovery occurred and translated rapidly into policy for the global response. Health Aff. 2012;31:1439–49.CrossRef

Marseille E, Hofmann PB, Kahn JG. HIV prevention before HAART in sub-Saharan Africa. Lancet. 2002;359:1851–6.PubMedCrossRef

Ford N, Calmy A, Mills EJ. The first decade of antiretroviral therapy in Africa. Glob Health. 2011;7:33.CrossRef

Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450–4.PubMedCrossRef

Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26:335–43.PubMedCrossRef

WHO UNAIDS UNICEF. Global HIV/AIDS Response, epidemic update and health sector progress torwards universal access-progress report. 2011. In: Geneva; 2011. http://www.who.int/hiv/pub/progress_report2011/en/index.html. Accessed 10 Dec 2012.

UNAIDS Global Report 2012. Geneva; 2012. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf. Accessed 10 Dec 2012.

• Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505. A multicountry, randomized controlled trial of early vs delayed ART in HIV-positive persons with CD4+ cell count between 350–550 cells/mm ³ , showing a 96 % reduction in HIV transmission in serodiscordant heterosexual couples in which the HIV -positive partner received early therapy.

• Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57. A modeling study illustrating that the theroretical strategy of universal voluntary HIV testing coupled with immediate ART treatment (TasP) could lead to HIV elimination in South Africa.

10.

Charlebois ED, Das M, Porco TC, Havlir DV. The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco. Clin Infect Dis. 2011;52:1046–9.PubMedCrossRef

11.

• Powers KA, Ghani AC, Miller WC, Hoffman IF, Pettifor AE, Kamanga G, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet. 2011;378:256–68. A modeling study evaluating the contribution of early acute HIV infection on HIV incidence in Malawi found that 38.4 % of HIV transmission could be attributable to sexual contact with individuals with early infection. The study suggests that HIV prevention interventions must target both chronic and acute infection in this sub-Saharan African setting.

12.

Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5:e11068.PubMedCrossRef

13.

Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376:532–9.PubMedCrossRef

14.

Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA. 2009;301:2380–2.PubMedCrossRef

15.

Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by ‘test and treat’ in hyperendemic settings. AIDS. 2010;24:729–35.PubMedCrossRef

16.

Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298.PubMedCrossRef

17.

Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomized controlled trial. Lancet. 2007;369:643–56.PubMedCrossRef

18.

Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomized trial. Lancet. 2007;369:657–66.PubMedCrossRef

19.

Paltiel AD, Walensky RP, Schackman BR, Seage 3rd GR, Mercincavage LM, Weinstein MC, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145:797–806.PubMedCrossRef

20.

Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484–94.PubMed

21.

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.PubMedCrossRef

22.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–74.PubMedCrossRef

23.

• Hull MW, Wu Z, Montaner JS. Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention. Curr Opin HIV AIDS. 2012;7:579–86. A review article which discusses treatment as prevention in the framework of “Seek, Test, Treat and Retain,” with each step in the framework essential for optimization of ART as an effective HIV prevention strategy.

24.

Eaton JW, Johnson LF, Salomon JA, Barnighausen T, Bendavid E, Bershteyn A, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9:e1001245.PubMedCrossRef

25.

• Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8:e1001056. A review article summarizing linkage and pre-ART retention across 28 studies in Africa. The median proportion of patient retained from HIV testing to receipt of CD4 count results or clinical stage (ie, linkage to care) was 59 % (35 %–8 %), from staging to ART eligiblity was 46 % (31 %–95 %) and from ART eligiblity to ART initiation was 68 % (14 %–84 %). Majority of studies only reported 1 category.

26.

Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub Saharan Africa, 2007–2009: systematic review. Tropical Med Int Health. 2010;15:1–15.CrossRef

27.

• Mugglin C, Estill J, Wandeler G, Bender N, Egger M, Gsponer T, et al. Loss to program between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health. 2012. doi:10.1111/j.1365-3156.2012.03089.x. A review or 29 studies from sub-Saharan Africa including 148,912 patients which reports of 100 patients with an HIV positive test, 72 % have a CD4 cell count measurement, 40 % were eligible for ART and 25 % initiated ART.

28.

• Vital signs: HIV prevention through care and treatment--United States. MMWR Morb Mortal Wkly Rep. 2011;60:1618–23. Using 2010 surveillence data, this study estimates that 28 % of HIV-infected persons in the United States have viral load suppression.

29.

• Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793–800. A review illustrating that only small improvements in the magnitude of viral load suppression are achieved when 1 step in the HIV care continuum is improved; however, when all steps are improved to greater than 90 % fidelity, viral load suppression increased from 19 % to 66 %.

30.

Marks G, Gardner LI, Craw J, Giordano TP, Mugavero MJ, Keruly JC, et al. The spectrum of engagement in HIV care: do more than 19 % of HIV-infected persons in the US have undetectable viral load? Clin Infect Dis. 2011;53:1168–9. author’s reply 1169–70.PubMedCrossRef

31.

Andrews JR, Wood R, Bekker LG, Middelkoop K, Walensky RP. Projecting the benefits of antiretroviral therapy for HIV prevention: the impact of population mobility and linkage to care. J Infect Dis. 2012;206:543–51.PubMedCrossRef

32.

Anglaret X, Scott CA, Walensky RP, Ouattara E, Losina E, Moh R, et al. Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis. Antivir Ther. 2012. doi:10.3851/IMP2231.

33.

WHO. http://www.who.int/hiv/events/2012/world_aids_day/hiv_testing_counselling/en/index.html. Accessed 10 Dec 2012.

34.

Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1–17. quiz CE11–4.PubMed

35.

WHO. Antiretroviral therapy for HIV infection in infants and children: towards universal access. In. Geneva; 2010.

36.

Sekandi JN, Sempeera H, List J, Mugerwa MA, Asiimwe S, Yin X, et al. High acceptance of home-based HIV counseling and testing in an urban community setting in Uganda. BMC Publ Health. 2011;11:730.CrossRef

37.

Molesworth AM, Ndhlovu R, Banda E, Saul J, Ngwira B, Glynn JR, et al. High accuracy of home-based community rapid HIV testing in rural Malawi. J Acquir Immune Defic Syndr. 2010;55:625–30.PubMedCrossRef

38.

Tumwesigye E, Wana G, Kasasa S, Muganzi E, Nuwaha F. High uptake of home-based, district-wide, HIV counseling and testing in Uganda. AIDS Patient Care STDS. 2010;24:735–41.PubMedCrossRef

39.

Choko AT, Desmond N, Webb EL, Chavula K, Napierala-Mavedzenge S, Gaydos CA, et al. The uptake and accuracy of oral kits for HIV self-testing in high HIV prevalence setting: a cross-sectional feasibility study in Blantyre, Malawi. PLoS Med. 2011;8:e1001102.PubMedCrossRef

40.

Kharsany AB, Karim QA, Karim SS. Uptake of provider-initiated HIV testing and counseling among women attending an urban sexually transmitted disease clinic in South Africa - missed opportunities for early diagnosis of HIV infection. AIDS Care. 2010;22:533–7.PubMedCrossRef

41.

MacPherson P, Lalloo DG, Choko AT, Mann GH, Squire SB, Mwale D, et al. Suboptimal patterns of provider initiated HIV testing and counselling, antiretroviral therapy eligibility assessment and referral in primary health clinic attendees in Blantyre, Malawi. Trop Med Int Health. 2012;17:507–17.PubMedCrossRef

42.

Marks G, Gardner LI, Craw J, Crepaz N. Entry and retention in medical care among HIV-diagnosed persons: a meta-analysis. AIDS. 2010;24:2665–78.PubMedCrossRef

43.

• Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care. panel. Ann Intern Med. 2012;156:817–33. 2012 guidelines from the International Assocaition of Physicians in AIDS Care. based on review of 325 randomized, controlled trails and observational studies on linkage to care, retention in care, and ART adherence.

44.

• Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS. 2012;26:2059–67. The first systematic review of risk factors for poor linkage to ART care. Common barriers are transport/distance to clinic, stigma, and disclosure and suboptimal clinic operations.

45.

Christopoulos KA, Das M, Colfax GN. Linkage and retention in HIV care among men who have sex with men in the United States. Clin Infect Dis. 2011;52 Suppl 2:S214–22.PubMedCrossRef

46.

Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMedCrossRef

47.

Kelly JA, Otto-Salaj LL, Sikkema KJ, Pinkerton SD, Bloom FR. Implications of HIV treatment advances for behavioral research on AIDS: protease inhibitors and new challenges in HIV secondary prevention. Health Psychol. 1998;17:310–9.PubMedCrossRef

48.

Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA. 2004;292:224–36.PubMedCrossRef

49.

Ostrow DE, Fox KJ, Chmiel JS, Silvestre A, Visscher BR, Vanable PA, et al. Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS. 2002;16:775–80.PubMedCrossRef

50.

Losina E, Bassett IV, Giddy J, Chetty S, Regan S, Walensky RP, et al. The “ART” of linkage: pre-treatment loss to care after HIV diagnosis at 2 PEPFAR sites in Durban, South Africa. PLoS One. 2010;5:e9538.PubMedCrossRef

51.

Larson BA, Brennan A, McNamara L, Long L, Rosen S, Sanne I, et al. Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health. 2010;15 Suppl 1:43–7.PubMedCrossRef

52.

Kovacs SM. Mfaume J, Sabatier H, Nuwagaba-Biribonwoha M, Lamb G, Arthur A, et al. The identification of high levels of loss to follow-up (LTFU) among pre-ART patients with unknown ART eligibility in 5 regions of Tanzania. In: IAS. Washington, DC; 2012.

53.

El-Sadr WM, Coburn BJ, Blower S. Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. AIDS. 2011;25:2295–9.PubMedCrossRef

54.

Ulett KB, Willig JH, Lin HY, Routman JS, Abroms S, Allison J, et al. The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care STDS. 2009;23:41–9.PubMedCrossRef

55.

Kahn TR, Desmond M, Rao D, Marx GE, Guthrie BL, Bosire R, et al. Delayed initiation of antiretroviral therapy among HIV-discordant couples in Kenya. AIDS Care. 2012. doi:10.1080/09540121.2012.712660.

56.

Campsmith ML, Rhodes PH, Hall HI, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr. 2010;53:619–24.PubMed

57.

Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years–United States, 2008. MMWR Recomm Rep. 2008;57:1–12.PubMed

58.

Wilson DP. HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention. PLoS Med. 2012;9:e1001231.PubMedCrossRef

59.

Kharsany AB, Mlotshwa M, Frohlich JA, Zuma NY, Samsunder N, Karim SS, et al. HIV prevalence among high school learners – opportunities for school-based HIV testing programs and sexual reproductive health services. World Health Popul. 2012;13:43–50.PubMed

60.

Abdool Karim Q, Kharsany AB, Frohlich JA, Werner L, Mlotshwa M, Madlala BT, et al. HIV incidence in young girls in KwaZulu-Natal, South Africa–public health imperative for their inclusion in HIV biomedical intervention trials. AIDS Behav. 2012;16:1870–6.PubMedCrossRef

61.

Rabkin M, El-Sadr WM. Why reinvent the wheel? Leveraging the lessons of HIV scale-up to confront non-communicable diseases. Glob Public Health. 2011;6:247–56.PubMedCrossRef

62.

Wood R, Lawn SD. Antiretroviral treatment as prevention: impact of the 'test and treat' strategy on the tuberculosis epidemic. Curr HIV Res. 2011;9:383–92.PubMedCrossRef

63.

Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W. Xpert((R)) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn. 2010;10:937–46.PubMedCrossRef

64.

Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001270.PubMedCrossRef

65.

Babiker AG, Emery S, Fatkenheuer G, Gordin FM, Grund B, Lundgren JD, et al. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials. 2012. doi:10.1177/1740774512440342.

66.

Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS. 2007;21:1717–21.PubMedCrossRef

67.

El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–96.PubMedCrossRef

68.

Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman WJ, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther. 2008;13:177–87.PubMed

69.

Integrated Prevention Services for HIV Infection, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis for Persons Who Use Drugs Illicitly: Summary Guidance from CDC and the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2012;61:1–40.

70.

Konate I, Traore L, Ouedraogo A, Sanon A, Diallo R, Ouedraogo JL, et al. Linking HIV prevention and care for community interventions among high-risk women in Burkina Faso–the ARNS 1222 “Yerelon” cohort. J Acquir Immune Defic Syndr. 2011;57 Suppl 1:S50–4.PubMedCrossRef

71.

Barker PM, Mphatswe W, Rollins N. Antiretroviral drugs in the cupboard are not enough: the impact of health systems’ performance on mother-to-child transmission of HIV. J AIDS. 2011;56:e45.

72.

McNairy ML, El-Sadr WM. The HIV care continuum: no partial credit given. AIDS. 2012;26:1735–8.PubMedCrossRef

Titel: Antiretroviral Therapy for Prevention Is a Combination Strategy
verfasst von: Margaret L. McNairy
Myron Cohen
Wafaa M. El-Sadr
Publikationsdatum: 01.06.2013
Verlag: Current Science Inc.
Erschienen in: Current HIV/AIDS Reports / Ausgabe 2/2013
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-013-0152-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Antiretroviral Therapy for Prevention Is a Combination Strategy

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don’t We Know?

Reducing HIV and AIDS in Adolescents: Opportunities and Challenges

Antiretroviral Drug Regimens to Prevent Mother-To-Child Transmission of HIV: A Review of Scientific, Program, and Policy Advances for Sub-Saharan Africa

HIV Testing: Current Practice and Future Directions

Addressing Injecting Drug Use in Asia and Eastern Europe

Combination Prevention: New Hope for Stopping the Epidemic

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin